Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ketamine's secret in OCD: opioid system may hold key

NCT ID NCT05940324

Recruiting now Symptom relief Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Stanford study tests how ketamine quickly reduces OCD symptoms by blocking opioid receptors with naltrexone. 150 adults with OCD who haven't responded to standard treatments will receive ketamine plus either naltrexone or a placebo. The goal is to see if the opioid system is involved in ketamine's rapid effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ketamine (an FDA-approved anesthetic) and naltrexone (an opioid blocker)
What this could lead to
If successful, this could reveal how ketamine quickly reduces OCD symptoms, potentially leading to better treatments.
What could go wrong
This is an early Phase 2 study with only 150 participants, so results may not apply to everyone. Ketamine can cause side effects like dissociation and nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSESSIVE-COMPULSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obsessive-compulsive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBSESSIVE-COMPULSIVE DISORDER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Department of Psychiatry & Behavioral Sciences

    RECRUITING

    Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.